Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $4.50, but opened at $5.06. Aldeyra Therapeutics shares last traded at $4.91, with a volume of 505,507 shares trading hands.
A number of analysts have weighed in on ALDX shares. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. ValuEngine upgraded shares of Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 target price on shares of Aldeyra Therapeutics in a report on Thursday, October 17th. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $24.19.
The firm has a fifty day simple moving average of $6.12 and a 200-day simple moving average of $5.90. The company has a market cap of $223.06 million, a PE ratio of -2.69 and a beta of 0.97. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.28.
In other Aldeyra Therapeutics news, CEO Todd C. Brady purchased 8,710 shares of Aldeyra Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was purchased at an average price of $5.68 per share, for a total transaction of $49,472.80. Following the transaction, the chief executive officer now directly owns 632,216 shares in the company, valued at $3,590,986.88. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Todd C. Brady purchased 8,680 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average price of $5.81 per share, with a total value of $50,430.80. Following the purchase, the chief executive officer now owns 623,506 shares in the company, valued at $3,622,569.86. The disclosure for this purchase can be found here. Insiders have purchased a total of 83,907 shares of company stock worth $456,912 in the last 90 days. 13.50% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio increased its position in Aldeyra Therapeutics by 7.5% in the 2nd quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 5,000 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Aldeyra Therapeutics in the second quarter valued at approximately $30,000. Bank of New York Mellon Corp increased its holdings in shares of Aldeyra Therapeutics by 7.7% in the second quarter. Bank of New York Mellon Corp now owns 75,353 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 5,406 shares during the period. Algert Global LLC raised its stake in shares of Aldeyra Therapeutics by 28.6% during the second quarter. Algert Global LLC now owns 29,840 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 6,631 shares during the last quarter. Finally, Private Advisors LLC raised its stake in shares of Aldeyra Therapeutics by 21.8% during the second quarter. Private Advisors LLC now owns 40,270 shares of the biotechnology company’s stock worth $242,000 after purchasing an additional 7,211 shares during the last quarter. Institutional investors own 60.40% of the company’s stock.
About Aldeyra Therapeutics (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Featured Story: What is the Shanghai Stock Exchange Composite Index?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.